Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call Transcript

So we see that as also a great opportunity as there are mechanisms within various countries for offering some level of reimbursement to spinal cord injury individuals. So we are anticipating continued growth in these regions relative to the North American growth that we see today. So I think overall, it’s we see a positive outlook there.

Sean Lee: And thanks for taking my questions.

Scott Davis: Thank you, Sean.

Operator: There are no further questions at this time. I would now like to turn the floor back over to Scott Davis for closing comments.

Scott Davis: Thank you, Maria. Before closing today’s call, I’d like to reiterate some key takeaways as we enter the final quarter of 2023. First, we’re building growth momentum with another strong quarter of EksoNR and Indego device sales, we continue to elevate the standard of care for neuro rehabilitation across the continuum of care. Second, the proposed rule for CMS if adopted in November to potentially expand coverage for Ekso Indego personal to thousands of spinal cord injury patients, we fully support the proposal to further enhance potential access for Medicare and Medicaid beneficiaries. Third, we’re starting to see promising results from our commercial strategy for EVO with a record unit sales quarter. Supported by our new contract manufacturer, we’re poised to take the next step in bringing these innovative devices to customers worldwide.

And finally, we continue to execute on our plan to achieve scale and positive cash flow through revenue growth, product line expansion and operational improvements. We look forward to updating you on our progress ahead. We want to thank you all for joining us today.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.